Barbara Burtness, MD, discusses potential immunotherapy agents that may assist in the treatment of head and neck cancers.
Barbara Burtness, MD, Clinical Research Program Leader, Head and Neck Cancers Program,Co-Director, Developmental Therapeutics Research Program,Professor of Medicine (Medical Oncology), Yale Cancer Center, discusses potential immunotherapy agents that may assist in the treatment of head and neck cancers.
<<<
Advances in Subsequent Therapies Shake Up Sequencing of ccRCC Treatment
April 25th 2024With the approval of belzutifan and other newer data for treating patients with recurrent renal cell carcinoma, the state of subsequent therapies is advancing beyond the reuse of frontline options with impacts on duration of response and quality of life.
Read More
Ornstein Advises on Starting Dose and Management of Lenvatinib in RCC
April 21st 2024During a Case-Based Roundtable® event, Moshe Ornstein, MD, MA, provided guidance on dosing and toxicity concerns in a patient treated with lenvatinib plus pembrolizumab for advanced renal cell carcinoma.
Read More